Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Army
Federal Trade Commission
Deloitte
Mallinckrodt
Chinese Patent Office

Generated: August 24, 2019

DrugPatentWatch Database Preview

Tafamidis - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for tafamidis and what is the scope of tafamidis freedom to operate?

Tafamidis is the generic ingredient in two branded drugs marketed by Foldrx Pharms and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tafamidis has fifty patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for tafamidis
International Patents:50
US Patents:5
Tradenames:2
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 42
Clinical Trials: 18
Patent Applications: 31
DailyMed Link:tafamidis at DailyMed
Synonyms for tafamidis
2-(3,5-Dichloro-phenyl)-benzooxazole-6-carboxylic acid
2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid
2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid
2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid
2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid
3096AH
3MI
4his
594839-88-0
6-Benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)-
839D880
8FG9H9D31J
A14111
AK222900
AKOS017550076
AN-27718
BCP29089
BDBM50197883
C14H7Cl2NO3
CHEBI:78538
CHEMBL2103837
CS-2821
D09673
DB-072645
DB11644
Discontinued until Pfizer approves it for our agreement""
DTXSID00208185
FT-0674793
Fx 1006
FX-1006
FX-1006A|||2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
GTPL8378
HY-14852
KS-00000TIG
MFCD16621109
SCHEMBL442508
Tafamidis (USAN/INN)
Tafamidis [USAN:INN]
tafamidisum
UNII-8FG9H9D31J
VS-0125
Z2588039578
ZINC43206271

US Patents and Regulatory Information for tafamidis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Foldrx Pharms VYNDAQEL tafamidis meglumine CAPSULE;ORAL 211996-001 May 3, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Foldrx Pharms VYNDAQEL tafamidis meglumine CAPSULE;ORAL 211996-001 May 3, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Foldrx Pharms VYNDAQEL tafamidis meglumine CAPSULE;ORAL 211996-001 May 3, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Foldrx Pharms VYNDAQEL tafamidis meglumine CAPSULE;ORAL 211996-001 May 3, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for tafamidis

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1587821 1290005-6 Sweden ➤ Sign Up PRODUCT NAME: TAFAMIDIS; REG. NO/DATE: EU/1/11/717/001 20111116
1587821 126 5003-2012 Slovakia ➤ Sign Up PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116
1587821 CR 2012 00006 Denmark ➤ Sign Up PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116
1587821 2012/007 Ireland ➤ Sign Up PRODUCT NAME: VYNDAQEL- TAFAMIDIS MEGLUMINE; REGISTRATION NO/DATE: EU/1/11/717/001 20111116
1587821 382 Finland ➤ Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
UBS
Harvard Business School
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.